Gene therapy offers another promising avenue, with liver-directed delivery systems aiming to restore ABCC6 expression [5]. Although no curative treatment currently exists for PXE, a combination of targeted symptomatic management and emerging experimental strategies holds promise for altering the disease trajectory in the future. This evidence concerns the gene ABCC6 and autosomal recessive inherited pseudoxanthoma elasticum.